Merck & Co., Inc. 8-K

What Happened

• Merck & Co., Inc. announced it closed an underwritten public offering on May 22, 2026, issuing $6.0 billion aggregate principal amount of senior unsecured notes across seven series under its Form S-3ASR registration. The offering included fixed-rate and floating-rate notes with maturities from 2028 to 2056 and was issued under the company’s existing indenture with U.S. Bank Trust National Association as trustee.

Key Details

• Total issued: $6,000,000,000 aggregate principal amount across seven series.
• Series and terms:
  • $500 million Floating Rate Notes due 2028
  • $1,000 million 4.300% Notes due 2028
  • $500 million 4.650% Notes due 2031
  • $1,000 million 4.950% Notes due 2033
  • $1,500 million 5.200% Notes due 2036
  • $500 million 5.750% Notes due 2046
  • $1,000 million 5.850% Notes due 2056
• The notes were issued under the company’s January 6, 2010 indenture; officers’ certificates and the company’s legal opinion (from Executive VP & General Counsel Jennifer Zachary) were filed as exhibits to the 8-K.
• The prospectus/registration used: Form S-3ASR (Registration No. 333-278066).

Why It Matters

• This transaction increases Merck’s outstanding debt by $6.0 billion across near-term and long-term maturities, which will affect the company’s future interest obligations and capital structure.
• The 8-K does not specify the use of proceeds; investors should monitor subsequent disclosures (e.g., in periodic filings) for how Merck deploys the funds and for any impact on credit metrics.